Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

by Christophe Moreno, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt
Published 2018

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

by Christophe Moreno, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt
Published 2018

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: Results from the 2-year roadmap strategy

by Teerha Piratvisuth, Piyawat Komolmit, Henry L.Y. Chan, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Mário G. Pessoa, Eduardo Fassio, Suzane K. Ono, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Michael Manns, Alkaz Uddin, Yuhong Dong, Aldo Trylesinski
Published 2018

Telbivudine versus lamivudine in patients with chronic hepatitis B

by Ching Lung Lai, Edward Gane, Yun Fan Liaw, Chao Wei Hsu, Satawat Thongsawat, Yuming Wang, Yagang Chen, E. Jenny Heathcote, Jens Rasenack, Natalie Bzowej, Nikolai V. Naoumov, Adrian M. Di Bisceglie, Stefan Zeuzem, Young Myoung Moon, Zachary Goodman, George Chao, Barbara Fielman Constance, Nathaniel A. Brown
Published 2018